• English

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    ​Cystic Fibrosis


    Cystic Fibrosis (CF) is an autosomal recessive disorder that results from defective activity of the CF transmembrane conductance regulator (CFTR protein). Newborns are
    typically asymptomatic, though some may present with a meconium ileus or poor weight gain. If an infant is not screened and/or is left untreated, symptoms begin to appear in childhood and can include progressive lung disease, pancreatic insufficency, and poor nutritional uptake/weight gain.
    Incidence: ~1/3200; more common in Caucasians (esp. Northern European descent)
    Diagnosis: The newborn screen measures immunoreactive trypsinogen (IRT), an enzyme secreted by the pancreas. Infants who have an elevated IRT on the initial screen will be identified as having a borderline result and a repeat screen will be requested on this initial report (this is known as the IRT/IRT method). If the baby has two elevated IRT levels on the screen, follow up with sweat chloride testing is needed to confirm the diagnosis.
    Treatment: Affected children require life-long enzyme treatment, respiratory therapy, and monitoring by both primary care and speciality providers.
    If treated promptly, children with cystic fibrosis can be expected to develop and gain
    weight appropriately. Even with treatment, bacterial endobronchitis, pancreatic insufficiency, and infertility can occur. Affected children should be monitored for pulmonary function and proper growth and weight gain.
    False Positives: Common, especially in babies who spend time in the NICU. Some of these babies will end up being carriers. Maryland does not incorporate DNA testing for CFTR as part of the newborn screen.